Septerna Upgrade: Potential 46% Gain

Septerna Incorporateds stock surged by 21% on November 14th following Wells Fargo analyst Derek Archilas upgrade to Overweight and new price target of $28 per share. Archilas confidence in SEP-four-seven-nines safety profile and potential advantages over earlier programs led to this upgrade. Two upcoming events, SEP-four-seven-nines Phase One trials and SEP-six-three-ones Phase One update, could further boost the stock. This upgrade reflects a positive outlook on Septernas drug development pipeline and GPCR-targeting treatments.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.